Y Intercept (Hong Kong) LTD Taysha Gene Therapies, Inc. Transaction History
Y Intercept (Hong Kong) LTD
- $1.44 Billion
- Q4 2024
Shares
1 transactions
Others Institutions Holding TSHA
# of Institutions
129Shares Held
150MCall Options Held
48KPut Options Held
7.8K-
Avoro Capital Advisors LLC New York, NY20MShares$36.4 Million0.5% of portfolio
-
Morgan Stanley New York, NY17.6MShares$32.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$21.4 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$19.8 Million0.3% of portfolio
-
Octagon Capital Advisors LP New York, NY10.5MShares$19 Million4.03% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $88M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...